Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer

Advances in Urology

Volumn , Issue , 2012, Pages

  Kohli, Manish ^a   Qin, Rui ^a   Jimenez, Rafael ^a   Dehm, Scott M ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866235420     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/781459     Document Type: Review

References (108)

1. Siegel R., Ward E., Brawley O., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CAA Cancer Journal for Clinicians 2011 61 4 212 236
2. Huggins C., Prostatic cancer treated by orchiectomy, the five year results. The Journal of the American Medical Association 1946 131 7 576 581 10.1001/jama.1946.02870240008003
3. Huggins C., Hodges C. V., Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Journal of Urology 2002 168 1 9 12 2-s2.0-0036636871
4. Howlader N., Noone A. M., Krapcho M., SEER Cancer Statistics Review, 19762008 2011 Bethesda, Md, USA National Cancer Institute
5. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J., A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. The New England Journal of Medicine 1989 321 7 419 424 2-s2.0-0024324367 (Pubitemid 19211484)
6. Denis L. J., Keuppens F., Smith P. H., Whelan P., Carneiro de Moura J. L., Newling D., Bono A., Sylvester R., Maximal androgen blockade: final analysis of EORTC phase III trial 30853. European Urology 1998 33 2 144 151 2-s2.0-0031907685 10.1159/000019546 (Pubitemid 28073756)
7. Eisenberger M. A., Blumenstein B. A., Crawford E. D., Miller G., McLeod D. G., Loehrer P. J., Wilding G., Sears K., Culkin D. J., Thompson I. M., Bueschen A. J., Lowe B. A., Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. The New England Journal of Medicine 1998 339 15 1036 1042 2-s2.0-0032497522 10.1056/NEJM199810083391504 (Pubitemid 28457865)
8. Dalesio O., Van Tinteren H., Clarke M., Peto R., Schroder F. H., Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. The Lancet 2000 355 9214 1491 1498 2-s2.0-0034728828 (Pubitemid 30237355)
9. Keating N. L., O'Malley A. J., Smith M. R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2006 24 27 4448 4456 2-s2.0-33749058933 10.1200/JCO.2006.06. 2497 (Pubitemid 46630983)
10. Weinstein I. B., Joe A., Oncogene addiction. Cancer Research 2008 68 9 3077 3080 2-s2.0-44849093562 10.1158/0008-5472.CAN-07-3293
11. Garraway L. A., Sellers W. R., Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews Cancer 2006 6 8 593 602 2-s2.0-33746565431 10.1038/nrc1947 (Pubitemid 44140858)
12. Russell D. W., Wilson J. D., Steroid 5 α -reductase: two genes/two enzymes. Annual Review of Biochemistry 1994 63 25 61 2-s2.0-0028173882
13. Lubahn D. B., Brown T. R., Simental J. A., Higgs H. N., Migeon C. J., Wilson E. M., French F. S., Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proceedings of the National Academy of Sciences of the United States of America 1989 86 23 9534 9538 2-s2.0-0024306555 10.1073/pnas.86.23.9534 (Pubitemid 20010461)
14. Lavery D. N., McEwan I. J., Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochemical Journal 2005 391 3 449 464 2-s2.0-27744511919 10.1042/BJ20050872 (Pubitemid 41634771)
15. Lavery D. N., McEwan I. J., The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics. Biochemical Society Transactions 2006 34 6 1054 1057 2-s2.0-34248649845 10.1042/BST0341054 (Pubitemid 46768987)
16. Heemers H. V., Tindall D. J., Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Reviews 2007 28 7 778 808 2-s2.0-37349118115 10.1210/er.2007-0019 (Pubitemid 350294296)
17. Isaacs J. T., Furuya Y., Berges R., The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Seminars in Cancer Biology 1994 5 5 391 400 2-s2.0-0028528315 (Pubitemid 124006792)
18. Vicini F. A., Vargas C., Abner A., Kestin L., Horwitz E., Martinez A., Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Journal of Urology 2005 173 5 1456 1462 2-s2.0-17144395627 10.1097/01.ju.0000157323.55611.23 (Pubitemid 40524749)
19. Smith J. A. Jr., Lange P. H., Janknegt R. A., Abbou C. C., DeGery A., Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. Journal of Urology 1997 157 4 1329 1334 2-s2.0-0030897726 10.1016/S0022-5347(01)64963-2 (Pubitemid 27130808)
20. Small E. J., Roach M., Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Seminars in Oncology 2002 29 3 264 273 2-s2.0-0036275786 10.1053/sonc.2002.32902 (Pubitemid 34620443)
21. Ross R. W., Xie W., Regan M. M., Pomerantz M., Nakabayashi M., Daskivich T. J., Sartor O., Taplin M. E., Kantoff P. W., Oh W. K., Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008 112 6 1247 1253 2-s2.0-41149138104 10.1002/cncr.23304 (Pubitemid 351429739)
22. Quinn D. I., Henshall S. M., Sutherland R. L., Molecular markers of prostate cancer outcome. European Journal of Cancer 2005 41 6 858 887 2-s2.0-16244376500 10.1016/j.ejca.2004.12.035 (Pubitemid 40461690)
23. Kohli M., Tindall D. J., New developments in the medical management of prostate cancer. Mayo Clinic Proceedings 2010 85 1 77 86 2-s2.0-73649094457 10.4065/mcp.2009.0442
24. Attard G., Richards J., De Bono J. S., New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Research 2011 17 7 1649 1657 2-s2.0-79953320228 10.1158/1078-0432.CCR-10- 0567
25. Chen Y., Clegg N. J., Scher H. I., Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. The Lancet Oncology 2009 10 10 981 991 2-s2.0-70349395222 10.1016/S1470-2045(09)70229-3
26. Culig Z., Bartsch G., Androgen axis in prostate cancer. Journal of Cellular Biochemistry 2006 99 2 373 381 2-s2.0-33746073145 10.1002/jcb.20898 (Pubitemid 44435555)
27. Knudsen K. E., Scher H. I., Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical Cancer Research 2009 15 15 4792 4798 2-s2.0-68049140791 10.1158/1078-0432.CCR-08-2660
28. Pienta K. J., Bradley D., Mechanisms underlying the development of androgen-independent prostate cancer. Clinical Cancer Research 2006 12 6 1665 1671 2-s2.0-33645690200 10.1158/1078-0432.CCR-06-0067
29. Sun J., Liu W., Adams T. S., Sun J., Li X., Turner A. R., Chang B., Jin W. K., Siqun L. Z., Isaacs W. B., Xu J., DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007 67 7 692 700 2-s2.0-34248139271 10.1002/pros.20543 (Pubitemid 46709438)
30. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., Chen L., Ewing C. M., Eisenberger M. A., Carducci M. A., Nelson W. G., Yegnasubramanian S., Luo J., Wang Y., Xu J., Isaacs W. B., Visakorpi T., Bova G. S., Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine 2009 15 5 559 565 2-s2.0-67349257845 10.1038/nm.1944
31. Mao X., Yu Y., Boyd L. K., Ren G., Lin D., Chaplin T., Kudahetti S. C., Stankiewicz E., Xue L., Beltran L., Gupta M., Oliver R. T. D., Lemoine N. R., Berney D. M., Young B. D., Lu Y. J., Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Research 2010 70 13 5207 5212 2-s2.0-77954380634 10.1158/0008-5472.CAN-09-4074
32. Holcomb I. N., Young J. M., Coleman I. M., Salari K., Grove D. I., Li H., True L. D., Roudier M. P., Morrissey C. M., Higano C. S., Nelson P. S., Vessella R. L., Trask B. J., Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Research 2009 69 19 7793 7802 2-s2.0-70350223620 10.1158/0008-5472.CAN-08-3810
33. Ruiz C., Lenkiewicz E., Evers L., Holley T., Robeson A., Kiefer J., Demeure M. J., Hollingsworth M. A., Shen M., Prunkard D., Rabinovitch P. S., Zellweger T., Mousses S., Trent J. M., Carpten J. D., Bubendorf L., Von Hoff D., Barrett M. T., Advancing a clinically relevant perspective of the clonal nature of cancer. Proceedings of the National Academy of Sciences of the United States of America 2011 108 29 12054 12059 2-s2.0-79961066627 10.1073/pnas.1104009108
34. Kumar A., White T. A., MacKenzie A. P., Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proceedings of the National Academy of Sciences of the United States of America 2011 108 41 17087 17092 10.1073/pnas.1108745108
35. Robbins C. M., Tembe W. A., Baker A., Sinari S., Moses T. Y., Beckstrom-Sternberg S., Beckstrom-Sternberg J., Barrett M., Long J., Chinnaiyan A., Lowey J., Suh E., Pearson J. V., Craig D. W., Agus D. B., Pienta K. J., Carpten J. D., Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Research 2011 21 1 47 55 2-s2.0-78651521293 10.1101/gr.107961.110
36. Taylor B. S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B. S., Arora V. K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J. E., Wilson M., Socci N. D., Lash A. E., Heguy A., Eastham J. A., Scher H. I., Reuter V. E., Scardino P. T., Sander C., Sawyers C. L., Gerald W. L., Integrative genomic profiling of human prostate cancer. Cancer Cell 2010 18 1 11 22 2-s2.0-77954255681 10.1016/j.ccr.2010.05.026
37. Berger M. F., Lawrence M. S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A. Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., Onofrio R., Carter S. L., Park K., Habegger L., Ambrogio L., Fennell T., Parkin M., Saksena G., Voet D., Ramos A. H., Pugh T. J., Wilkinson J., Fisher S., Winckler W., Mahan S., Ardlie K., Baldwin J., Simons J. W., Kitabayashi N., MacDonald T. Y., Kantoff P. W., Chin L., Gabriel S. B., Gerstein M. B., Golub T. R., Meyerson M., Tewari A., Lander E. S., Getz G., Rubin M. A., Garraway L. A., The genomic complexity of primary human prostate cancer. Nature 2011 470 7333 214 220 2-s2.0-79951497419 10.1038/nature09744
38. Edwards J., Krishna N. S., Grigor K. M., Bartlett J. M. S., Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer 2003 89 3 552 556 2-s2.0-0042978480 10.1038/sj.bjc.6601127 (Pubitemid 37026442)
39. Ford O. H. III, Gregory C. W., Kim D., Smitherman A. B., Mohler J. L., Androgen receptor gene amplification and protein expression in recurrent prostate cancer. Journal of Urology 2003 170 5 1817 1821 2-s2.0-0141954183 10.1097/01.ju.0000091873.09677.f4 (Pubitemid 37254935)
40. Linja M. J., Savinainen K. J., Saramäki O. R., Tammela T. L. J., Vessella R. L., Visakorpi T., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 2001 61 9 3550 3555 2-s2.0-0035328474 (Pubitemid 32694958)
41. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O. P., In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995 9 4 401 406 2-s2.0-0028944138
42. Leversha M. A., Han J., Asgari Z., Danila D. C., Lin O., Gonzalez-Espinoza R., Anand A., Lilja H., Heller G., Fleisher M., Scher H. I., Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical Cancer Research 2009 15 6 2091 2097 2-s2.0-63449110302 10.1158/1078-0432.CCR-08-2036
43. Attard G., Swennenhuis J. F., Olmos D., Reid A. H. M., Vickers E., A'Hern R., Levink R., Coumans F., Moreira J., Riisnaes R., Oommen N. B., Hawche G., Jameson C., Thompson E., Sipkema R., Carden C. P., Parker C., Dearnaley D., Kaye S. B., Cooper C. S., Molina A., Cox M. E., Terstappen L. W. M. M., De Bono J. S., Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Research 2009 69 7 2912 2918 2-s2.0-66149098947 10.1158/0008-5472.CAN-08-3667
44. Bergerat J. P., Céraline J., Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Human Mutation 2009 30 2 145 157 2-s2.0-59749095425 10.1002/humu.20848
45. Brooke G. N., Bevan C. L., The role of androgen receptor mutations in prostate cancer progression. Current Genomics 2009 10 1 18 25 2-s2.0-65949113815 10.2174/138920209787581307
46. Gottlieb B., Beitel L. K., Nadarajah A., Paliouras M., Trifiro M., The androgen receptor gene mutations database: 2012 update. Human Mutation 2012 33 5 887 894 2-s2.0-84857963838 10.1002/humu.22046
47. Tilley W. D., Wilson C. M., Marcelli M., McPhaul M. J., Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Research 1990 50 17 5382 5386 2-s2.0-0025045495 (Pubitemid 20302992)
48. Thompson J., Hyytinen E. R., Haapala K., Rantala I., Helin H. J., Jänne O. A., Palvimo J. J., Koivisto P. A., Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Laboratory Investigation 2003 83 12 1709 1713 2-s2.0-0347364754 10.1097/01.LAB.0000107262.40402.44 (Pubitemid 38018533)
49. Haapala K., Hyytinen E. R., Roiha M., Laurila M., Rantala I., Helin H. J., Koivisto P. A., Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Laboratory Investigation 2001 81 12 1647 1651 2-s2.0-0035212580 (Pubitemid 33144427)
50. Hyytinen E. R., Haapala K., Thompson J., Lappalainen I., Roiha M., Rantala I., Helin H. J., Jänne O. A., Vihinen M., Palvimo J. J., Koivisto P. A., Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Laboratory Investigation 2002 82 11 1591 1598 2-s2.0-0036847896 (Pubitemid 35332918)
51. Taplin M. E., Bubley G. J., Shuster T. D., Frantz M. E., Spooner A. E., Ogata G. K., Keer H. N., Balk S. P., Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England Journal of Medicine 1995 332 21 1393 1398 2-s2.0-0029011116 10.1056/NEJM199505253322101
52. Taplin M. E., Bubley G. J., Ko Y. J., Small E. J., Upton M., Rajeshkumar B., Balk S. P., Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 1999 59 11 2511 2515 2-s2.0-0033152164 (Pubitemid 29269089)
53. Taplin M. E., Rajeshkumar B., Halabi S., Werner C. P., Woda B. A., Picus J., Stadler W., Hayes D. F., Kantoff P. W., Vogelzang N. J., Small E. J., Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. Journal of Clinical Oncology 2003 21 14 2673 2678 2-s2.0-0042130389 10.1200/JCO.2003.11.102 (Pubitemid 46606310)
54. Steinkamp M. P., O'Mahony O. A., Brogley M., Rehman H., LaPensee E. W., Dhanasekaran S., Hofer M. D., Kuefer R., Chinnaiyan A., Rubin M. A., Pienta K. J., Robins D. M., Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Research 2009 69 10 4434 4442 2-s2.0-66249135684 10.1158/0008-5472.CAN-08-3605
55. Buchanan G., Greenberg N. M., Scher H. I., Harris J. M., Marshall V. R., Tilley W. D., Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 2001 7 5 1273 1281 2-s2.0-0034895975 (Pubitemid 32708680)
56. Zhao X. Y., Malloy P. J., Krishnan A. V., Swami S., Navone N. M., Peehl D. M., Feldman D., Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Medicine 2000 6 6 703 706 2-s2.0-0034125195 10.1038/76287 (Pubitemid 30398797)
57. Culig Z., Hobisch A., Cronauer M. V., Cato A. C. B., Hittmair A., Radmayr C., Eberle J., Bartsch G., Klocker H., Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology 1993 7 12 1541 1550 2-s2.0-0027724728 10.1210/me.7.12.1541 (Pubitemid 24034236)
58. Culig Z., Stober J., Gast A., Peterziel H., Hobisch A., Radmayr C., Hittmair A., Bartsch G., Cato A. C., Klocker H., Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detection and Prevention 1996 20 1 68 75 2-s2.0-0030037779 (Pubitemid 2627098)
59. Bentel J. M., Tilley W. D., Androgen receptors in prostate cancer. Journal of Endocrinology 1996 151 1 1 11 2-s2.0-0029802619 10.1677/joe.0.1510001 (Pubitemid 26359499)
60. Veldscholte J., Ris-Stalpers C., Kuiper G. G. J. M., Jenster G., Berrevoets C., Claassen E., Van Rooij H. C. J., Trapman J., Brinkmann A. O., Mulder E., A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 1990 173 2 534 540 2-s2.0-0025644325 10.1016/S0006-291X(05)80067-1
61. Buchanan G., Yang M., Harris J. M., Nahm H. S., Han G., Moore N., Bentel J. M., Matusik R. J., Horsfall D. J., Marshall V. R., Greenberg N. M., Tilley W. D., Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology 2001 15 1 46 56 2-s2.0-17744378148 10.1210/me.15.1.46 (Pubitemid 32156040)
62. Chen G., Wang X., Zhang S., Lu Y., Sun Y., Zhang J., Li Z., Lu J., Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005 63 4 395 406 2-s2.0-18644372239 10.1002/pros.20191 (Pubitemid 40664351)
63. Tilley W. D., Buchanan G., Hickey T. E., Bentel J. M., Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research 1996 2 2 277 285 2-s2.0-0029915052 (Pubitemid 26074615)
64. Han G., Buchanan G., Ittmann M., Harris J. M., Yu X., DeMayo F. J., Tilley W., Greenberg N. M., Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America 2005 102 4 1151 1156 2-s2.0-12844274300 10.1073/pnas.0408925102 (Pubitemid 40170741)
65. He B., Kemppainen J. A., Wilson E. M., FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. The Journal of Biological Chemistry 2000 275 30 22986 22994 2-s2.0-0034725648 10.1074/jbc.M002807200 (Pubitemid 30646187)
66. Dehm S. M., Regan K. M., Schmidt L. J., Tindall D. J., Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cells. Cancer Research 2007 67 20 10067 10077 2-s2.0-35448947810 10.1158/0008-5472.CAN-07-1267 (Pubitemid 47621258)
67. Shi X. B., Ma A. H., Tepper C. G., Xia L., Gregg J. P., Gandour-Edwards R., Mack P. C., Kung H. J., DeVere White R. W., Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004 60 3 257 271 2-s2.0-3242755999 10.1002/pros.20039 (Pubitemid 38971837)
68. Dehm S. M., Schmidt L. J., Heemers H. V., Vessella R. L., Tindall D. J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 2008 68 13 5469 5477 2-s2.0-48549089747 10.1158/0008-5472.CAN-08-0594
69. Guo Z., Yang X., Sun F., Jiang R., Linn D. E., Chen H., Chen H., Kong X., Melamed J., Tepper C. G., Kung H. J., Brodie A. M. H., Edwards J., Qiu Y., A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 2009 69 6 2305 2313 2-s2.0-65549168746 10.1158/0008-5472.CAN-08-3795
70. Hu R., Dunn T. A., Wei S., Isharwal S., Veltri R. W., Humphreys E., Han M., Partin A. W., Vessella R. L., Isaacs W. B., Bova G. S., Luo J., Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 2009 69 1 16 22 2-s2.0-58249110391 10.1158/0008-5472.CAN-08-2764
71. Sun S., Sprenger C. C. T., Vessella R. L., Haugk K., Soriano K., Mostaghel E. A., Page S. T., Coleman I. M., Nguyen H. M., Sun H., Nelson P. S., Plymate S. R., Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 2010 120 8 2715 2730 2-s2.0-77955296562 10.1172/JCI41824
72. Watson P. A., Chen Y. F., Balbas M. D., Wongvipat J., Socci N. D., Viale A., Kim K., Sawyers C. L., Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2010 107 39 16759 16765 2-s2.0-78049280194 10.1073/pnas.1012443107
73. Li Y., Alsagabi M., Fan D., Bova G. S., Tewfik A. H., Dehm S. M., Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research 2011 71 6 2108 2117 2-s2.0-79952772097 10.1158/0008-5472.CAN-10-1998
74. Li Y., Hwang T. H., Oseth L., AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. In press
75. Kumar-Sinha C., Tomlins S. A., Chinnaiyan A. M., Recurrent gene fusions in prostate cancer. Nature Reviews Cancer 2008 8 7 497 511 2-s2.0-45849103492 10.1038/nrc2402
76. Cai C., Wang H., Xu Y., Chen S., Balk S. P., Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Research 2009 69 15 6027 6032 2-s2.0-68049131467 10.1158/0008-5472.CAN-09-0395
77. Wu C., Wyatt A. W., Lapuk A. V., Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology 2012 227 1 53 61 2-s2.0-84862777198 10.1002/path.3987
78. Friedlander T. W., Roy R., Tomlins S. A., Ngo V. T., Kobayashi Y., Azameera A., Rubin M. A., Pienta K. J., Chinnaiyan A., Ittmann M. M., Ryan C. J., Paris P. L., Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Research 2012 72 3 616 625 2-s2.0-84856530618 10.1158/0008-5472.CAN-11-2079
79. Saloniemi T., Jokela H., Strauss L., Pakarinen P., Poutanen M., The diversity of sex steroid action: novel functions of hydroxysteroid (17 β) dehydrogenases as revealed by genetically modified mouse models. Journal of Endocrinology 2012 212 1 27 40 2-s2.0-83455260425 10.1530/JOE-11-0315
80. El Gammal A. T., Brüchmann M., Zustin J., Isbarn H., Hellwinkel O. J. C., Köllermann J., Sauter G., Simon R., Wilczak W., Schwarz J., Bokemeyer C., Brümmendorf T. H., Izbicki J. R., Yekebas E., Fisch M., Huland H., Graefen M., Schlomm T., Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clinical Cancer Research 2010 16 1 56 64 2-s2.0-74949116742 10.1158/1078-0432. CCR-09-1423
81. Heemers H., Verrijdt G., Organe S., Claessens F., Heyns W., Verhoeven G., Swinnen J. V., Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. The Journal of Biological Chemistry 2004 279 29 30880 30887 2-s2.0-3142739478 10.1074/jbc.M401615200 (Pubitemid 38938024)
82. Debes J. D., Schmidt L. J., Huang H., Tindall D. J., p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Research 2002 62 20 5632 5636 2-s2.0-0037108955 (Pubitemid 35204712)
83. Debes J. D., Sebo T. J., Lohse C. M., Murphy L. M., Haugen D. A. L., Tindall D. J., p300 in prostate cancer proliferation and progression. Cancer Research 2003 63 22 7638 7640 2-s2.0-0345275876 (Pubitemid 37466688)
84. Lenz H. J., The use and development of germline polymorphisms in clinical oncology. Journal of Clinical Oncology 2004 22 13 2519 2521 2-s2.0-4344619012 10.1200/JCO.2004.04.900 (Pubitemid 41103738)
85. Ross R. W., Oh W. K., Xie W., Pomerantz M., Nakabayashi M., Sartor O., Taplin M. E., Regan M. M., Kantoff P. W., Freedman M., Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. Journal of Clinical Oncology 2008 26 6 842 847 2-s2.0-39749137117 10.1200/JCO.2007.13.6804 (Pubitemid 351398074)
86. Kohli M., Riska S. M., Mahoney D. W., Chai H. S., Hillman D. W., Rider D. N., Costello B. A., Qin R., Lamba J., Sahasrabudhe D. M., Cerhan J. R., Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clinic Proceedings 2012 87 3 240 246 2-s2.0-84857980986 10.1016/j.mayocp.2011.09.009
87. Yang M., Xie W., Mostaghel E., Nakabayashi M., Werner L., Sun T., Pomerantz M., Freedman M., Ross R., Regan M., Sharifi N., Figg W. D., Balk S., Brown M., Taplin M. E., Oh W. K., Lee G. S. M., Kantoff P. W., SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2011 29 18 2565 2573 2-s2.0-79959294088 10.1200/JCO.2010.31.2405
88. Huang C.-N., Huang S.-P., Pao J.-B., Hour T.-C., Chang T.-Y., Lan Y.-H., Lu T.-L., Lee H.-Z., Juang S.-H., Wu P.-P., Huang C.-Y., Hsieh C.-J., Bao B.-Y., Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. Journal of Internal Medicine 2012 271 5 499 509 2-s2.0-84860227006 10.1111/j.1365-2796.2011.02449.x
89. Huang C.-N., Huang S.-P., Pao J.-B., Chang T.-Y., Lan Y.-H., Lu T.-L., Lee H.-Z., Juang S.-H., Wu P.-P., Pu Y.-S., Hsieh C.-J., Bao B.-Y., Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Annals of Oncology 2012 23 3 707 713 2-s2.0-84857607620 10.1093/annonc/mdr264
90. Sun T., Lee G. S. M., Werner L., Pomerantz M., Oh W. K., Kantoff P. W., Freedman M. L., Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiology Biomarkers and Prevention 2010 19 7 1871 1878 2-s2.0-77954498376 10.1158/1055-9965.EPI-10-0216
91. De Bono J. S., Attard G., Adjei A., Pollak M. N., Fong P. C., Haluska P., Roberts L., Melvin C., Repollet M., Chianese D., Connely M., Terstappen L. W. M. M., Gualberto A., Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clinical Cancer Research 2007 13 12 3611 3616 2-s2.0-34250783291 10.1158/1078-0432.CCR-07-0268 (Pubitemid 46955123)
92. Shaffer D. R., Leversha M. A., Danila D. C., Lin O., Gonzalez-Espinoza R., Gu B., Anand A., Smith K., Maslak P., Doyle G. V., Terstappen L. W. M. M., Lilja H., Heller G., Fleisher M., Scher H. I., Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clinical Cancer Research 2007 13 7 2023 2029 2-s2.0-34247502671 10.1158/1078-0432.CCR-06- 2701 (Pubitemid 46649868)
93. Danila D. C., Fleisher M., Scher H. I., Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research 2011 17 12 3903 3912 2-s2.0-79959269553 10.1158/1078-0432.CCR-10-2650
94. Jiang Y., Palma J. F., Agus D. B., Wang Y., Gross M. E., Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clinical Chemistry 2010 56 9 1492 1495 2-s2.0-77956357165 10.1373/clinchem.2010.143297
95. de Jong D., Verbeke S. L. J., Meijer D., Hogendoorn P. C. W., Bovee J. V. M. G., Szuhai K., Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Research Notes 2011 4, article 1 2-s2.0-78650793762 10.1186/1756-0500-4-1
96. Buchan N. C., Goldenberg S. L., Intermittent androgen suppression for prostate cancer. Nature Reviews Urology 2010 7 10 552 560 2-s2.0-77958028795 10.1038/nrurol.2010.141
97. Oldenhuis C. N. A. M., Oosting S. F., Gietema J. A., de Vries E. G. E., Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 2008 44 7 946 953 2-s2.0-42649085349 10.1016/j.ejca.2008.03.006
98. Simon R., The use of genomics in clinical trial design. Clinical Cancer Research 2008 14 19 5984 5993 2-s2.0-58149151278 10.1158/1078-0432.CCR-07-4531
99. Simon R., Wang S. J., Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics Journal 2006 6 3 166 173 2-s2.0-33646047815 10.1038/sj.tpj.6500349 (Pubitemid 43811567)
100. Simon R., Maitournam A., Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004 10 20 6759 6763 2-s2.0-6044278144 10.1158/1078-0432.CCR-04-0496 (Pubitemid 39383023)
101. Liu A., Liu C., Li Q., Yu K. F., Yuan V. W., A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clinical Trials 2010 7 5 537 545 2-s2.0-78649932251 10.1177/1740774510378695
102. Wang S. J., O'Neill R. T., Hung H. M. J., Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007 6 3 227 244 2-s2.0-34648840242 10.1002/pst.300 (Pubitemid 47455262)
103. Sargent D. J., Conley B. A., Allegra C., Collette L., Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 2005 23 9 2020 2027 2-s2.0-15744374441 10.1200/JCO.2005.01.112 (Pubitemid 46211382)
104. Freidlin B., Simon R., Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005 11 21 7872 7878 2-s2.0-27744537954 10.1158/1078-0432.CCR-05-0605 (Pubitemid 41611633)
105. Eickhoff J. C., Kim K., Beach J., Kolesar J. M., Gee J. R., A Bayesian adaptive design with biomarkers for targeted therapies. Clinical Trials 2010 7 5 546 556 2-s2.0-78649918672 10.1177/1740774510372657
106. Lee J. J., Gu X., Liu S., Bayesian adaptive randomization designs for targeted agent development. Clinical Trials 2010 7 5 584 596 2-s2.0-78649956851 10.1177/1740774510373120
107. Ryan C. J., Halabi S., Ou S. S., Vogelzang N. J., Kantoff P., Small E. J., Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a Cancer and Leukemia Group B study. Clinical Cancer Research 2007 13 7 2030 2037 2-s2.0-34247523157 10.1158/1078-0432.CCR-06-2344 (Pubitemid 46649869)
108. Efstathiou E., Titus M., Tsavachidou D., Tzelepi V., Wen S., Hoang A., Molina A., Chieffo N., Smith L. A., Karlou M., Troncoso P., Logothetis C. J., Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of Clinical Oncology 2012 30 6 637 643 2-s2.0-84857603814 10.1200/JCO.2010.33.7675